{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:46:36Z","timestamp":1749627996911},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00198-013-2515-2","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T11:08:52Z","timestamp":1380712132000},"page":"339-347","source":"Crossref","is-referenced-by-count":24,"title":["The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis"],"prefix":"10.1007","volume":"25","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Amling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kandenwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"2515_CR1","volume-title":"Physician\u2019s guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2003","unstructured":"National Osteoporosis Foundation (2003) Physician\u2019s guide to prevention and treatment of osteoporosis. Excerpta Medica, Belle Mead"},{"key":"2515_CR2","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018","journal-title":"Lancet"},{"key":"2515_CR3","first-page":"52","volume":"110","author":"P Hadji","year":"2013","unstructured":"Hadji P, Klein S, Gothe H, H\u00e4ussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) The epidemiology of osteoporosis\u2014Bone Evaluation Study (BEST): an analysis of routine health insurance data. Dtsch Arztebl Int 110:52\u201357","journal-title":"Dtsch Arztebl Int"},{"key":"2515_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","volume":"6","author":"O Str\u00f6m","year":"2012","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis JA, Compston J, Cooper C, McCloskey EV, J\u00f6nsson B (2012) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59\u2013155","journal-title":"Arch Osteoporos"},{"key":"2515_CR5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00198-009-0958-2","volume":"20","author":"FH Hooven","year":"2009","unstructured":"Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris E, Watts NB, Anderson FA Jr (2009) The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 20:1107\u20131116","journal-title":"Osteoporos Int"},{"issue":"6","key":"2515_CR6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/annrheumdis-2012-201451","volume":"72","author":"D Prieto-Alhambra","year":"2013","unstructured":"Prieto-Alhambra D, Nogues X, Javaid MK, Wyman A, Arden NK, Azagra R, Cooper C, Adachi JD, Boonen S, Chapurlat RD, Compston JE, Gehlbach SH, Greenspan SL, Hooven FH, Netelenbos JC, Pfeilschifter J, Rossini M, Sambrook PN, Silverman S, Siris ES, Watts NB, D\u00edez-P\u00e9rez A (2013) An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis 72(6):911\u20137","journal-title":"Ann Rheum Dis"},{"key":"2515_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/qjmed\/hcq259","volume":"104","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281\u2013300","journal-title":"QJM"},{"key":"2515_CR8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"2515_CR9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"2515_CR10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, ABC Project Team (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691\u2013705","journal-title":"Br J Clin Pharmacol"},{"key":"2515_CR11","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"2515_CR12","first-page":"25","volume":"3","author":"A H\u00f6er","year":"2009","unstructured":"H\u00f6er A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, H\u00e4ussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25\u201330","journal-title":"Patient Prefer Adherence"},{"key":"2515_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","volume":"19","author":"FJ Penning-van Beest","year":"2008","unstructured":"Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511\u2013517","journal-title":"Osteoporos Int"},{"issue":"2 Suppl","key":"2515_CR14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstr\u00f6m F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3\u2013S13","journal-title":"Am J Med"},{"key":"2515_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21\u201326","journal-title":"Osteoporos Int"},{"key":"2515_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"B Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259\u2013262","journal-title":"Osteoporos Int"},{"key":"2515_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"2515_CR18","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","volume":"24","author":"JA Simon","year":"2002","unstructured":"Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871\u20131886","journal-title":"Clin Ther"},{"key":"2515_CR19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"D Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Sch\u00f6ter KH (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298\u2013307","journal-title":"Am J Med"},{"key":"2515_CR20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","volume":"34","author":"S Adami","year":"2004","unstructured":"Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection once every 3\u00a0months. Bone 34:881\u2013889","journal-title":"Bone"},{"key":"2515_CR21","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"2515_CR22","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"2515_CR23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","volume":"23","author":"G Bianchi","year":"2012","unstructured":"Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769\u20131778","journal-title":"Osteoporos Int"},{"key":"2515_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2008.09.006","volume":"44","author":"AC Feldstein","year":"2009","unstructured":"Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153\u2013159","journal-title":"Bone"},{"key":"2515_CR25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-011-1620-3","volume":"23","author":"E Barrett-Connor","year":"2012","unstructured":"Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US\u2122. Osteoporos Int 23:733\u2013741","journal-title":"Osteoporos Int"},{"key":"2515_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303\u2013310","journal-title":"Joint Bone Spine"},{"key":"2515_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11154-010-9138-0","volume":"11","author":"S Silverman","year":"2010","unstructured":"Silverman S, Gold DT (2010) Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 11:275\u2013280","journal-title":"Rev Endocr Metab Disord"},{"key":"2515_CR28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594","journal-title":"Curr Med Res Opin"},{"key":"2515_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"2515_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CP201632","volume":"50","author":"V Ziller","year":"2012","unstructured":"Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis-analysis using a large-scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50:315\u2013322","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2515_CR31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00198-006-0294-8","volume":"18","author":"E Seeman","year":"2007","unstructured":"Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, J\u00f6nsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles\u2019 heel of anti-fracture efficacy. Osteoporos Int 18:711\u2013719","journal-title":"Osteoporos Int"},{"key":"2515_CR32","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/S0002-9378(99)70732-5","volume":"180","author":"PM Sarrel","year":"1999","unstructured":"Sarrel PM (1999) Improving adherence to hormone replacement therapy with effective patient-physician communication. Am J Obstet Gynecol 180:S337\u2013S340","journal-title":"Am J Obstet Gynecol"},{"key":"2515_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517\u2013525","journal-title":"Arch Intern Med"},{"key":"2515_CR34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.4065\/77.10.1044","volume":"77","author":"S Greenspan","year":"2002","unstructured":"Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044\u20131052","journal-title":"Mayo Clin Proc"},{"key":"2515_CR35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1185\/030079904125003548","volume":"20","author":"JA Eisman","year":"2004","unstructured":"Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699\u2013705","journal-title":"Curr Med Res Opin"},{"key":"2515_CR36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bone.2012.02.639","volume":"50","author":"EM Dennison","year":"2012","unstructured":"Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, D\u00edez-P\u00e9rez A, Anderson FA Jr, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Greenspan SL, Premaor M, Cooper C, Investigators GLOW (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288\u20131293","journal-title":"Bone"},{"key":"2515_CR37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MLR.0b013e31818afa1c","volume":"47","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2009) Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 47:334\u2013341","journal-title":"Med Care"},{"key":"2515_CR38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00198-011-1555-8","volume":"23","author":"V Breuil","year":"2012","unstructured":"Breuil V, Cortet B, Cott\u00e9 FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, Roborel de Climens A, Legrand E (2012) Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 23:445\u2013455","journal-title":"Osteoporos Int"},{"key":"2515_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-006-0206-y","volume":"18","author":"B H\u00e4ussler","year":"2007","unstructured":"H\u00e4ussler B, Gothe H, G\u00f6l D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany\u2014the BoneEVA Study. Osteoporos Int 18:77\u201384","journal-title":"Osteoporos Int"},{"key":"2515_CR40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"2515_CR41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00198-008-0586-2","volume":"19","author":"JA Sunyecz","year":"2008","unstructured":"Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421\u20131429","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2515-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2515-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T06:14:07Z","timestamp":1564294447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2515-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2515-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]}}}